Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Liabilities and Shareholders Equity (2019 - 2025)

Silo Pharma's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $6.4 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 25.47% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $26.3 million, down 15.8%, while the annual FY2024 figure was $7.4 million, 4.32% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $6.4 million at Silo Pharma, down from $6.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $13.0 million in Q3 2022 and bottomed at $5.0 million in Q2 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $8.6 million (2024), against an average of $8.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 1262.3% in 2021 before it tumbled 37.03% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $10.5 million in 2021, then increased by 10.99% to $11.6 million in 2022, then plummeted by 33.47% to $7.7 million in 2023, then dropped by 4.32% to $7.4 million in 2024, then fell by 13.86% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Liabilities and Shareholders Equity are $6.4 million (Q3 2025), $6.7 million (Q2 2025), and $5.9 million (Q1 2025).